[First Reprint]

ASSEMBLY, No. 3424

STATE OF NEW JERSEY

217th LEGISLATURE

INTRODUCED MARCH 7, 2016

 


 

Sponsored by:

Assemblyman† JOSEPH A. LAGANA

District 38 (Bergen and Passaic)

Assemblyman† PATRICK J. DIEGNAN, JR.

District 18 (Middlesex)

Assemblywoman† NANCY J. PINKIN

District 18 (Middlesex)

Assemblywoman† VALERIE VAINIERI HUTTLE

District 37 (Bergen)

Assemblywoman† MARLENE CARIDE

District 36 (Bergen and Passaic)

Assemblyman† RALPH R. CAPUTO

District 28 (Essex)

Assemblyman† BENJIE E. WIMBERLY

District 35 (Bergen and Passaic)

Assemblyman† PAUL D. MORIARTY

District 4 (Camden and Gloucester)

 

Co-Sponsored by:

Assemblymen Ciattarelli, Peterson, Giblin, A.M.Bucco, DiMaio, Assemblywoman Chaparro, Assemblyman Coughlin, Assemblywomen Jones, Phoebus, Assemblymen Space, Taliaferro, Assemblywomen Muoio, Rodriguez-Gregg, Jimenez, McKnight, Assemblymen Eustace, O'Scanlon, Assemblywoman Downey, Assemblyman Houghtaling and Assemblywoman Lampitt

 

 

SYNOPSIS

†††† Requires prescribers to discuss addiction risk associated with certain drugs prior to issuing prescription to minor patient.

 

CURRENT VERSION OF TEXT

†††† As reported by the Assembly Health and Senior Services Committee on December 5, 2016, with amendments.

††


An Act concerning prescription medications and supplementing Title 24 of the Revised Statutes.

 

†††† Be It Enacted by the Senate and General Assembly of the State of New Jersey:

 

†††† 1.††† a. A health care professional authorized to issue prescriptions shall, prior to issuing a prescription for 1[a Schedule II controlled dangerous substance or any] an1 opioid drug which is a 1[prescription drug as defined in section 2 of P.L.2003, c.280 (C.45:14-41)] Schedule II controlled dangerous substance1, discuss with a patient who is under 18 years of age and is an emancipated minor, or with the patientís parent or guardian if the patient is under 18 years of age and is not an emancipated minor, the risks of developing a physical or psychological dependence on the 1[controlled dangerous substance or prescription]1 opioid drug and, if the prescriber deems it appropriate, such alternative treatments as may be available.

†††† b.††† A prescriber who engages in a discussion required pursuant to subsection a. of this section shall 1[obtain from the person with whom the prescriber had the discussion a written acknowledgement that the discussion took place.† The written acknowledgement shall be included] include a note1 in the patientís medical record 1[and shall be on a form developed by the Director of the Division of Consumer Affairs in the Department of Law and Public Safety in consultation with such medical professional societies and associations as may be identified by the director] indicating that the discussion took place1.

†††† c.†††† 1[The Director of the Division of Consumer Affairs in the Department of Law and Public Safety shall develop and make available to prescribers guidelines for the discussion required pursuant to subsection a. of this section.

†††† d.]1† The discussion required under subsection a. of this section shall not be required prior to issuing a prescription to any patient who is currently receiving hospice care from a licensed hospice.

 

†††† 2.††† This act shall take effect immediately.